Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

Trade82 Feb. 4 at 6:10 AM

$GANX Looking at this slide, if the higher GluSph patients show big improvement, but the patients without elevated GluSph didn't show close to the same improvement, once we lower levels back to normal in 90 days will patients continue to see improvement? Or maybe it will just take longer in patients without elevated levels to start working? Guess these questions will be answered with data release.

0 · Reply

MQuick Feb. 4 at 12:56 AM

$GANX stock should be $10 plus right now

0 · Reply

AtomBull27 Feb. 4 at 12:11 AM

$GANX interesting they filed an 8-k for presentation update. Maybe because they presented the data a little differently? I don’t really see anything new on there. Wonder why..

1 · Reply

Jwa68 Feb. 3 at 11:36 PM

$GANX As promised... -increasing evidence of GT-02287 efficacy -statistically significant improvement in high GluSph cohort suggests potential efficacy in this patient population - PD patients with high GluSph could enrich Phase 2 - overall scores (n=13) still show stabilization and improvement meaning this drug can still be used for all comers -16/19 in open label extension, must be a perceived benefit - additional ongoing biomarker analysis means potential for more news ahead of AD/PD - updated analysis at AD/PD and other conferences - GT-02287 is Phase 2 ready Talk amongsts yourselves. 😉

2 · Reply

Lectin_Pectin Feb. 3 at 11:29 PM

$GANX Phase 2: Step 1) enroll only patients with elevated Glusph Step 2) grand slam And holy shit, do you see that, 6.17 pt improvement??? Damn. Huge magnitude of treatment effect. Raising asking price to $3 billion.

3 · Reply

ross929 Feb. 3 at 10:53 PM

$GANX now this is crazy. After 90-days.

1 · Reply

Pacsbull Feb. 3 at 9:57 PM

$GANX

0 · Reply

MQuick Feb. 3 at 9:31 PM

$GANX anyone care to take out the 165 shares at $1.82? I literally have $5 available cash or i would do it! 🫣😳

1 · Reply

Trade82 Feb. 3 at 9:28 PM

$GANX new sec filing informing about new company presentation slides

0 · Reply

Random_2wheels Feb. 3 at 8:56 PM

$GANX This is getting annoying.

0 · Reply

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Jan 6, 2026, 7:00 AM EST - 4 weeks ago

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Dec 18, 2025, 4:05 PM EST - 6 weeks ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Dec 18, 2025, 7:00 AM EST - 6 weeks ago

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

Nov 20, 2025, 7:00 AM EST - 2 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Nov 12, 2025, 7:00 AM EST - 2 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 7, 2025, 4:16 AM EST - 3 months ago

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

Oct 30, 2025, 7:00 AM EDT - 3 months ago

Gain Therapeutics to Present at Neuroscience 2025

Oct 16, 2025, 7:00 AM EDT - 3 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 6, 2025, 8:15 AM EDT - 4 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2025, 7:40 AM EDT - 4 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Sep 18, 2025, 7:41 AM EDT - 4 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Sep 4, 2025, 8:00 AM EDT - 5 months ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Aug 12, 2025, 7:00 AM EDT - 6 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Jul 24, 2025, 8:53 AM EDT - 6 months ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 16, 2025, 9:03 AM EDT - 7 months ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 15, 2025, 4:36 PM EDT - 7 months ago

Gain Therapeutics Announces Proposed Public Offering

Jun 30, 2025, 4:05 PM EDT - 7 months ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 8 months ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 8 months ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 14, 2025, 7:30 AM EDT - 9 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 9 months ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 9 months ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 9 months ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Mar 28, 2025, 8:30 AM EDT - 11 months ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 7:00 AM EDT - 11 months ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 11 months ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 11 months ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 1 year ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 1 year ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 31, 2024, 12:23 PM EST - 1 year ago

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Dec 23, 2024, 7:30 AM EST - 1 year ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jun 28, 2024, 4:39 PM EDT - 1 year ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 8:35 AM EDT - 1 year ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 13, 2024, 9:00 PM EDT - 1 year ago

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

May 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 29, 2024, 6:15 PM EDT - 1 year ago

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 14, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Trade82 Feb. 4 at 6:10 AM

0 · Reply

MQuick Feb. 4 at 12:56 AM

$GANX stock should be $10 plus right now

0 · Reply

AtomBull27 Feb. 4 at 12:11 AM

$GANX interesting they filed an 8-k for presentation update. Maybe because they presented the data a little differently? I don’t really see anything new on there. Wonder why..

1 · Reply

Jwa68 Feb. 3 at 11:36 PM

2 · Reply

Lectin_Pectin Feb. 3 at 11:29 PM

3 · Reply

ross929 Feb. 3 at 10:53 PM

$GANX now this is crazy. After 90-days.

1 · Reply

Pacsbull Feb. 3 at 9:57 PM

$GANX

0 · Reply

MQuick Feb. 3 at 9:31 PM

$GANX anyone care to take out the 165 shares at $1.82? I literally have $5 available cash or i would do it! 🫣😳

1 · Reply

Trade82 Feb. 3 at 9:28 PM

$GANX new sec filing informing about new company presentation slides

0 · Reply

Random_2wheels Feb. 3 at 8:56 PM

$GANX This is getting annoying.

0 · Reply

IwM Feb. 3 at 8:46 PM

$GANX 👃 I smell reversal here Added size

1 · Reply

Trade82 Feb. 3 at 8:40 PM

$GANX if you wondered what will be presented Ad/pd in march

2 · Reply

Jeffreyb7173 Feb. 3 at 8:36 PM

$GANX any chance the patients lost weight while taking this drug and they can rebrand it to compete against GLP1’s… that’s apparently the only drug anyone cares about.,. Totally insane!

0 · Reply

Pacsbull Feb. 3 at 8:31 PM

$GANX FIRST disease modifying drug for Parkinson’s disease. For less than $2, get in and get in quick

0 · Reply

mwb1 Feb. 3 at 8:25 PM

$GANX By the way, this is the first time that they've used "statistically significant" in relation to UPDRS scores: "Those individuals with elevated baseline CSF GluSph also benefitted from a statistically significant improvement in MDS-UPDRS Parts II and III scores of 6.17 points (p<0.05)" That's in 90 days! Bodes very well for the patients in the extension.

1 · Reply

MQuick Feb. 3 at 8:21 PM

$GANX so now we have a desrisked phase 2 asset that reverses PD symptoms in 90 days worth 87 million. Makes sense.

0 · Reply

Jwelz90 Feb. 3 at 8:17 PM

$GANX Eh, screw it. Added more.

2 · Reply

microcapspeculator Feb. 3 at 8:12 PM

$GANX Disease modifying by improving cascade and neuron survival.

2 · Reply

mwb1 Feb. 3 at 8:09 PM

$GANX This is an important slide. They are publicly stating that what they’ve shown in animal models they are now showing in Parkinson’s patients— the same things that improved animals are improving people, and for the same reasons. Most drugs fail in this step. This is a huge statement, which derisks phase 2 in a big way.

3 · Reply

Jwa68 Feb. 3 at 8:02 PM

$GANX Quite encouraging and perhaps a little telling is my first inclination after just a quick look. I will habe some thoughts after the close when i have time to digest. Stock is a steal here in my mind, a literal steal.

0 · Reply

mwb1 Feb. 3 at 7:58 PM

$GANX New corporate update available. Some great slides which add clarity around the 1b, the correlation between GluSph reductions and UPDRS scores, and the patients (16 of whom elected into the extension). https://gaintherapeutics.com/wp-content/uploads/2026/02/GANX-February-2026-Corporate-Deck-Final4.pdf

1 · Reply

Trade82 Feb. 3 at 7:57 PM

$GANX February Corporate presentation just added to website. Bunch of new slides.

0 · Reply

Market Cap	69.23M
Revenue (ttm)	0.00
Net Income (ttm)	-20.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	543,200
Avg Vol	1,496,002
Day's Range	N/A - N/A
Shares Out	38.46M
Stochastic %K	21%
Beta	0.06
Analysts	Strong Sell
Price Target	$7.60